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Background: In community-acquired pneumonia host inflammatory response against the causative microorganism
is necessary for infection resolution. However an excessive response can have deleterious effects. In addition to
antimicrobial effects, macrolide antibiotics are known to possess immunomodulatory properties.
We aimed to evaluate inflammatory cytokine profiles – both locally (bronchoalveolar lavage) and systemically
(blood) – in community-acquired pneumonia admitted patients after at least 72 hours of antibiotic treatment (with
and without macrolide containing regimens) and requiring bronchoscopic examination for inadequate response
due to infection progression and/or lack of clinical stability.
Methods: A prospective study was performed on 52 admitted patients who developed an inadequate response
after 72 hours of antibiotic treatment - non-responders community-acquired pneumonia - (blood and bronchoalveolar
lavage), and two control groups: 1) community-acquired pneumonia control (blood) and 2) non-infection control
(blood and bronchoalveolar lavage). Cytokine profiles (interleukin (IL)-6, IL-8, IL-10), tumour necrosis factor α and clinical
outcomes were assessed.
Results: Non–responders patients treated with macrolide containing regimens showed significantly lower levels of IL-6
and TNF-α in bronchoalveolar lavage fluid and lower IL-8 and IL-10 in blood than those patients treated with non-
macrolide regimens. Clinical outcomes showed that patients treated with macrolide regimens required fewer days to
reach clinical stability (p < 0.01) and shorter hospitalization periods (p < 0.01).
Conclusions: After 72 hours of antibiotic effect, patients who received macrolide containing regimens exhibited lower
inflammatory cytokine levels in pulmonary and systemic compartments along with faster stabilization of infectious
parameters.
Keywords: Community acquired pneumonia, Macrolides, Lung inflammationIntroduction
The majority of hospitalized community-acquired pneu-
monia (CAP) patients respond favorably to antibiotic
treatment but around 10% develop an inadequate re-
sponse to treatment that leads to a poorer prognosis [1].
Cytokines are important mediators that orchestrate the
inflammatory response and hence play an important role
in host defense against microorganisms. However, exces-
sive and persistent cytokine production [2] has been as-
sociated with a higher number of days needed to reach* Correspondence: rosmenend@gmail.com
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unless otherwise stated.clinical stability, treatment failure and increased mortal-
ity [3,4]. After antibiotic treatment, when the response
is adequate, inflammation decreases with a return to
homeostasis.
The immunomodulatory effects of macrolides benefit
the host due to their capacity to temper the production
of inflammatory cytokines [5-7]. Some recent observa-
tional studies have reported better outcomes in severe
CAP cases [8-12], when antibiotics regimens contained
macrolides. Others studies, though, have not reported
such improvement [13,14]. We hypothesized that anti-
biotic influence on cytokine production might have a
beneficiary effect upon the resolution of infectious param-
eters. Although systemic inflammation has been examinedl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with different antibiotics regimens is scarce.
The aims of the present study were to investigate 1)
lung and systemic inflammatory cytokine profiles in hos-
pitalized CAP patients after at least 72 hours of anti-
biotic treatment (with and without macrolide containing
regimens) and who required bronchoscopic examination
owing to an inadequate response consequent upon in-
fection progression and/or lack of clinical stability; and
2) the impact of macrolide containing regimens treat-
ment on clinical resolution parameters.
Methods
Study design
A prospective longitudinal study was conducted of ad-
mitted CAP patients requiring bronchoscopic examin-
ation due to an inadequate response to antibiotic
treatment after at least 72 hours of antibiotic treatment:
non-responders CAP (NCAP). The inclusion criteria for
the NCAP study group were: 1) clinical deterioration
with acute respiratory failure requiring ventilator sup-
port and/or septic shock; and/or 2) persistence of a high
temperature (≥38°C) and/or clinical symptoms, and/or
chest-X ray progression (>50% increase of infiltrates with
clinical symptoms) or empyema [3]. Patient enrolment
in the study was performed on the day of their broncho-
scopic examination when samples of bronchoalveolar
(BAL) fluid and blood were obtained.
Two control groups were included: 1) CAP control
group (CAP), comprised of patients of a similar age and
co-morbid condition who reached clinical stability after
72 hours of antibiotic treatment (temperature <37.2°C,
heart rate <100 beats/min, respiratory rate <24 breaths/
min, systolic blood pressure >90 mm Hg, and oxygen
saturation >90% or arterial oxygen tension >60 mm Hg
when patient was not receiving supplemental oxygen)
[15,16]; and 2) Non-infection control group, comprised
of patients without any infection for whom a bronchos-
copy had been scheduled due to peripheral lung nodules
or minor haemoptysis.
Exclusion criteria were: prior admission to hospital
(1 month), immunosuppressive treatment, HIV infec-
tion, or alternative diagnosis.
The study was approved by the Ethical Committee of
our hospital (approval number 2005/0141) and patients
signed the required informed consent form.
Data collection
The following data were collected: demographics, co-
morbid conditions, laboratory data, chest radiograph, ini-
tial pneumonia severity [17], microbiological tests (sputum
culture, urinary antigens of Legionella pneumophila and
Streptococcus pneumoniae, blood cultures and serology
for Chlamydophila pneumoniae, Mycoplasma pneumonia,Coxiella burnetii and Legionella pneumophila), and length
of hospital stay (LOS) which was calculated as the number
of days from admission until discharge.
Antimicrobial therapy received by patients was recorded
and classified as follows: beta-lactams (ceftriaxone/cefo-
taxime: 1–2 g/12-24 h, 1–2 g/8 h or co-amoxiclavulanate:
1–2 g/8 h) +macrolides (azithromycin: 500 mg/24 h);
fluoroquinolone (levofloxacin: 500 mg/12-24 h) in mono-
therapy, both as recommended by Spanish guidelines [18],
and beta-lactams + fluoroquinolone. Patients who received
any other combination of antibiotics were classified as
“other regimens”.
Biological samples collection
In both the NCAP and non-infection control group,
BAL fluid and blood samples were obtained on the day
of bronchoscopic examination. In the CAP control group,
blood samples were obtained at clinical stability, after at
least 72 hours of antibiotic treatment, and no BAL fluid
was obtained.
Bronchoalveolar lavage
BAL was collected according to recommended guide-
lines [19] by flexible videobronchoscope in the affected
lobe in NCAP patients and in the middle lobe in non-
infection controls. Five aliquots of sterile saline solution
were instilled and immediately aspirated. The first ali-
quot (20 mL) was discarded. The remaining four ali-
quots (30 mL each) were pooled together in a single
sterile glass: 50% of the retrieved fluid was sent to the
microbiology laboratory and the other 50% to the bio-
chemistry laboratory for cytokine measurement. The
mean ± SEM BAL fluid obtained for processing was
56 ± 2 ml. To eliminate remaining mucus, the samples
were filtered through two sheets of gauze. BAL fluid
sample was centrifuged at 353 × g for 5 min at 4°C. The
supernatant volume was measured and frozen at −80°C
until further analysis.
Blood samples
Venous blood samples were collected prior to the BAL pro-
cedure and were centrifuged at 1500 rpm for 10 minutes.
Plasma was separated, coded and frozen at −80°C until
further processing.
Cytokines determinations
The determination of cytokines levels [interleukin (IL)-6,
IL-8, IL-10 and tumour necrosis factor α (TNF-α)] were
analysed using the commercially available enzyme im-
munoassay (Pharmingen, BD Biociencias, Madrid, Spain)
according to the manufacturer’s protocol. The limits of
detection were 3 pg/ml for IL-6, 3 pg/ml for IL-8, 2 pg/ml
for IL-10 and 1 pg/ml for TNF-α.
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Statistical analysis was performed with the SPSS statis-
tical software package, version 12.0 (SPSS, Chicago, IL,
USA), and the GraphPad software (San Diego, CA,
USA). Chi-square and Mann–Whitney U tests were per-
formed for, respectively, the qualitative and quantitative
variables. Data are shown as mean ± SEM. Statistical sig-
nificance was considered at a p value of <0.05.
Results
Patient characteristics
86 patients were included: 52 NCAP, 15 CAP controls
and 19 non-infection controls. The main demographic
characteristics, comorbidity, initial pneumonia severity
and antimicrobial therapy for each group are shown in
Table 1. The median days of hospitalization prior to en-
rolment in the study was 5 days in the NCAP group and
4 in the CAP control group. The reasons for non-
response in the NCAP group were: 32 (61.5%) persistentTable 1 General characteristics, comorbidity, initial







Subjects, n 52 15 19
Age, years 61 ± 2 66 ± 4 61 ± 2 NS
Male/Female 31/21 12/3 16/3 NS
Current smoker, n 16 2 9 NS
Comorbidity, n
- Cerebrovascular disease 11(21) 3(20) 2(10) NS
- Heart disease 12(23) 3(20) 2(10) NS
- COPD 7(14) 7(46) 7(37) 0.01
PSI score 98 ± 4 102 ± 7 N/A NS
CRP (mg/dl) N/A
- At admission 232 ± 25 190 ± 30 NS
- At enrolment 165 ± 18 68 ± 21 0.05
Inhaled corticosteroids 2(29) 1(14) 0(15) NS
Systemic corticosteroids 2(29) 3(43) 0 NS
Antimicrobial therapyβ, n N/A
- Fluoroquinolone 6(12) 5(33)




- Others regimens** 15(28) 1(7)
Data are expressed as mean ± SEM or n(%). *Mann–Whitney U test and chi-square
test for continuous and categorical variables, respectively.
NCAP: non-responders pneumonia; CAP: community-acquired pneumonia;
COPD: chronic obstructive pulmonary disease; PSI score: Pneumonia Severity
Index score; CRP: C-reactive protein; NS: non-significant. N/A: not applicable.
βAntimicrobial therapy at enrolment of the study.
Other regimens **vancomycin, imipemen-cilastatin, piperacillin-tazobactam,
amikacin, clindamycin, ceftazidime, ertapenem and linezolid.fever and clinical worsening; 15 (28.8%) radiological
progression- 2 of these with pleural effusion-; and 5
(9.6%) respiratory failure requiring invasive ventilation.
Six patients died during hospitalization.
General characteristics, comorbidity conditions and
corticosteroids treatment according to macrolides regi-
mens in the NCAP and CAP control groups are shown
in Table 2. The median macrolide dosages for patients at
the point of enrolment for the study were: 5 dosages of
azithromycin 500 mg/24 h iv for the NCAP group and 3
dosages of azithromycin 500 mg/24 h iv for the CAP
control group.
Microbiological results
In the NCAP group, etiological microorganism was identi-
fied in 24 patients (46%). The most frequent isolated
pathogen was Streptococcus pneumoniae (13 patients
25%): 3 in both blood culture and urinary antigen, 7 urin-
ary antigen, 1 blood culture and 2 in BAL. The aetiological
diagnosis with regard to macrolide regimens or otherwise,
is provided in Table 3. In the CAP control group,
aetiological diagnosis was reached in 5 patients (33.3%): 4
Streptococcus pneumoniae, 1 Pseudomonas aeruginosa.
Cytokine levels in BAL and blood samples
NCAP group
The comparison between patients treated with and with-
out macrolide regimens showed: In BAL fluid, IL-6 and
TNF-α were significantly lower in patients treated with
macrolide regimens (216 ± 66 vs 590 ± 230 pg/mL; p = 0.01
and 1 ± 0.3 vs 4 ± 0.8; p = 0.03 respectively), (Figure 1), with
a trend towards lower IL-8 levels (p = 0.06). After exclud-
ing patients with inhaled or systemic concomitant cortico-
steroids treatment, lower IL-6 levels in BAL (111 ± 32 vs
706 ± 300; p = 0.004) were confirmed.
In blood, IL-8 and IL-10 were significantly lower in
patients with macrolide regimens (42 ± 13 vs 57 ± 13;
p = 0.04, and 15 ± 6 vs 27 ± 7; p = 0.01 respectively),
(Figure 2), with a trend towards lower IL-6 levels (p = 0.06).
No detectable levels of TNF-α in blood were obtained.
In the subset of patients without corticosteroids concomi-
tant treatment we corroborated lower IL-6, IL-8 and
IL-10 levels in patients with macrolide regimens (96 ± 39
vs 305 ± 137, p = 0.05; 35 ± 14 vs 52 ± 14, p = 0.05; and
14 ± 6 vs 23 ± 6, p = 0.02, respectively).
CAP control group
No significant differences in blood cytokine levels were
observed between patients treated with macrolide con-
taining regimens and those treated with non-macrolide
regimens (Figure 2) in the whole group and after exclud-
ing patients with corticosteroid concomitant treatment.
Similarly, no differences were observed between COPD
and non-COPD patients.
Table 2 General characteristics, comorbidity and corticosteroids treatment in NCAP and CAP control groups according











Subjects, n 23 29 9 6
Age, years 60 ± 4 63 ± 3 NS 78 ± 3 70 ± 9 NS
Male/Female 12/11 19/10 NS 7/2 5/1 NS
Co-morbidity, n
- Cerebrovascular disease 4(17) 7(24) NS 3(33) 0 NS
- Heart disease 4(17) 8(28) NS 2(22) 1(17) NS
- COPD 1(4) 6(21) NS 3(33) 4(67) NS
Risk class of Fine NS NS
I-II 7(30) 6(21) 0 1(17)
III-V 16(70) 23(79) 9(100) 5(83)
Inhaled corticosteroid 0 2(7) NS 1(11) 0 NS
Systemic corticosteroid 3(13) 6(21) NS 4(44) 2(33) NS
Data are expressed as mean ± SEM or n(%). *Mann–Whitney U test and chi-square test for continuous and categorical variables, respectively.
αMacrolide regimens: beta-lactam (ceftriaxone, cefotaxime or co-amoxi-clavulanate +macrolide (azithromicyn: 500 mg/24 h).
βNon-macrolide regimens: fluoroquinolone (levofloxacin: 500 mg/12-24 h) in monotherapy or beta-lactam + fluoroquinolone or other regimens.
NCAP: non-responders pneumonia; CAP: community-acquired pneumonia; COPD: chronic obstructive pulmonary disease; NS: non-significant. N/A: not applicable.
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The relationship between the days needed to reach clin-
ical stability and LOS according to treatment with
macrolide and non-macrolide regimens in the NCAP
group and the CAP control group is shown in Table 4.
In the NCAP group, patients with macrolide contain-
ing regimens required fewer days than patients with
non-macrolide regimens to reach clinical stability, and
had shorter LOS. After excluding patients with cortico-
steroid concomitant treatment we confirmed signifi-
cantly shorter LOS in patients treated with macrolide
regimens (13 ± 1.5 vs 24 ± 4, p = 0.01, respectively) and
fewer days to reach clinical stability (8 ± 1 vs 16 ± 3, p =




(n 23) (n 29)
Microorganisms
- Streptococcus pneumoniae 5 (21.7) 8(27.6)
- Pseudomonas aeruginosa 2(8.7) 5(17.2)
- Escherichia coli 0 2(6.9)
- Streptococcus spp 1(4.3) 1(3.4)
- MRSA 0 2(6.9)
- Polymicrobial 0 7(24.1)
Pathogens isolated 8(34.8) 16(55.2)
Date are presented as n (%).
NCAP: non-responders pneumonia; CAP: community-acquired pneumonia; MRSA: mwhole CAP control group and after excluding those with
corticosteroid treatments.
Discussion
The most important findings of our study are: 1) Levels
of IL-6 and TNF-α in BAL and of IL-8 and IL-10 in
blood were significantly lower in NCAP patients who re-
ceived macrolide containing regimens than in those
treated with non-macrolide regimens; and 2) there were
improved clinical outcomes, such as earlier clinical sta-
bility and shorter LOS, in patients who received macro-
lide containing regimens. Our main findings were also
confirmed in patients without any concomitant cortico-
steroid treatment.p patients according to macrolide containing regimens
CAP control
lide regimens Macrolide regimens Non-macrolideregimens









Figure 1 BAL cytokine levels in the NCAP group according to macrolide containing regimens and non-macrolide regimens. Data
excluding corticosteroids users are also depicted. Legend: Data are presented as mean ± SEM. **/* macrolide regimens vs non-macrolide regimens;
###/## vs control. *: p < 0.05; **: p≤ 0.01; ##: p < 0.05; ###: p < 001. NCAP: non-responders pneumonia; IL: interleukin; TNF-α: tumour necrosis factor-α.
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ity at 72 hours after antibiotic treatment developed
raised cytokine inflammatory levels in both compart-
ments, pulmonary and systemic, thereby following a
pattern similar to that found in previous reports. Persist-
ently high levels of IL-6, IL-8 and IL-10 in BAL fluid or
serum have been found in severe pneumonia and NCAP
[2,4,20,21], reflecting an ongoing inflammation. In this
context, declining levels of biomarkers, IL-6, IL-8 and
IL-10, along with apoptosis of neutrophils have also been
reported at clinical stability [22].
The beneficial impact of controlling inflammatory re-
sponse through immunodulatory agents in CAP has
received significant attention [5,23-26]. In our study,
NCAP patients treated with macrolide containing regi-
mens exhibited a trend towards IL-8 BAL fluid levels
and significantly lower IL-6 and TNF-α compared to pa-
tients treated with non-macrolide regimens. Moreover,
in blood our results also confirmed lower levels of IL-6,
IL-8 and IL-10 in the NCAP patients treated with
macrolide regimens, while in those CAP control patientswho attained clinical stability no significant differences
were detected.
Despite the recognized role of macrolides in tempering
inflammation, there are very few studies on humans of
this [25]. In cases of CAP, Demartini et al. [27] compared
systemic cytokines levels of clarithromycin (500 mg twice
a day for 7 days) and amoxicylin (1 g three times a day for
7 days) in patients before starting antibiotic therapy, at the
3rd and 7th days of therapy. Clarithromycin decreased sig-
nificantly levels of IL-6 and increased levels of IL-10 at the
3rd and 7th days in comparison with basal levels. In a
randomized clinical study of ventilator associated pneu-
monia patients, Spyridaki et al. [28] analyzed the effect of
the clarithromycin and placebo on cytokines over six
consecutive days. The serum ratio of IL-10 to TNF-α de-
creased in the clarithromycin group compared to the pla-
cebo group.
It is also worth highlighting that in our study the effect
of macrolides was not apparent in CAP patients with
clinical stability, which indicates that, at that point, cyto-
kine levels were already reduced.
Figure 2 Blood cytokine levels in NCAP and CAP control group
according to macrolide containing regimens and non-macrolide
regimens. Legend: Data are presented as mean ± SEM. *: p < 0.05;
**: p ≤ 0.01. NCAP: non-responders pneumonia; CAP: community-
acquired pneumonia; IL: interleukin. Non-infection control group is
represented as dashed line.
Table 4 Comparison of clinical outcomes in NCAP and
CAP control group according to macrolide containing






-Macrolide regimens (n 23) 8(6–12) 0.007 12(10–21) 0.007
-Non-macrolide regimens (n 29) 14(8–27) 20(13–36)
CAP control
-Macrolide regimens (n 9) 6(3–10) 0.6 9(7–16) 0.8
-Non-macrolide regimens (n 6) 6(3–6) 9(8–12)
Data are presented as median and interquartile range. p# values were
calculated using the Mann–Whitney U-test.
NCAP: non-responders pneumonia; CAP: community-acquired pneumonia;
LOS: Length of stay.
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press the production of NF-kB and the synthesis and/or
secretion of pro-inflammatory cytokines, and decrease in-
flux and neutrophil activity [23]. In animal models with
pneumonia, the reduction of chemokine secretion and
cytokine levels was demonstrated when microorganisms
were resistant to macrolides, suggesting that benefits wereindependent of antimicrobial activity [29]. Sanz et al. [30],
reported in respect of an animal study in vivo that erythro-
mycin exerts anti-inflammatory activity and inhibits
leukocyte recruitment in the lung. In in vitro studies, re-
sults suggest that macrolides exhibit a suppressive effect
on cytokines in models of acute inflammation [25], viral
bronchiolitis [31] and ventilator-induced lung injury [32].
Anderson et al. [33], have reported that the production of
pneumolysin, a key virulence factor of the pneumococcus,
is attenuated by exposure of this microbial pathogen to
clarithromycin.
The beneficial impact of macrolides on outcomes in
CAP cases has been recently evaluated in a systematic
review [23] that identified 6 uncontrolled studies: 4 in
favor of macrolides [12,34-36] and 2 without beneficial
effects [13,14]. Moreover, in severe sepsis due to CAP,
Restrepo et al. [10], found that patients who received
macrolide therapy in comparison with those patients
who did not receive it were associated with decreased
mortality at 30 days (11% vs 29%, p < 0.001) and at
60 days (12% vs 34%, p < 0.001) even in those cases with
macrolide-resistant pathogens. Recently, Rodrigo et al.
[37], studied the benefits of beta-lactams/macrolide
combination therapy over single beta-lactams therapy
for the treatment of immunocompetent adults hospital-
ized with CAP. They reported that the 30 days in-
patient death rate was lower in the combination therapy
than in the single therapy group (23% vs 26.8%; OR 0.81,
95% CI 0.72 to 0.93, p = 0.001). In bacteremic pneumonia
Metersky et al. [11], reported that the use of macrolides
was associated with lower in-hospital mortality, 30-day
mortality and readmission within 30 days of discharge.
Interestingly, the gain in survival and improved out-
comes with regard to dual antibiotic therapy, mainly in
severe and bacteremic pneumococcal CAP, is associated
principally with treatments that include macrolides [38]
instead of beta-lactams plus fluoroquinolones [39]. This
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macrolides.
In vitro and in vivo studies have shown that, due to
their immunomodulatory effects, macrolides decrease
inflammatory response, independently of antibacterial
activity, through different pathways: inhibition of NF-kβ
along with reduction of proinflammatory cytokines pro-
duction; an inhibitory effect on the release of inflamma-
tory cells such as polymorphonuclear cells; and an effect
on structural cells of the respiratory tract that improves
mucociliary clearance and increases the expression of
molecules tight junctions or β-defensin [24]. In addition,
macrolide antibiotics have an effect on microorganisms
because they may inhibit virulence factors production,
biofilm formation and protein synthesis [24]. Moreover,
a macrolide combination therapy could provide better
coverage for atypical microorganisms.
Some other important factors can influence the in-
flammatory response in CAP patients, such as cortico-
steroids treatment and comorbidity as COPD [40]. In
our study, we corroborated our results with lower IL-6
in BAL and IL-8 and IL-10 in blood after excluding pa-
tients treated with corticosteroids.
Our findings are consistent with previous studies as
they show an improvement of clinical outcomes (faster
clinical stability and shorter LOS) and a reduction of
cytokine levels in CAP patients with acute lung infection
who are treated with macrolide containing regimens.
These findings could be related to decreased levels of
the pro-inflammatory cytokines IL-6, IL-8 and TNF-α,
and support the value of macrolides for their beneficial
effect over immunomodulatory properties.
The present study has some limitations that should be
considered.
First, the absence of BAL fluid samples in the CAP
control group as, for ethical reasons, we did not perform
a bronchoscopy in patients with adequate response.
There are few human studies that report compartmental
inflammatory response in patients with CAP, probably
because of the ethical difficulties of performing BAL in
non-severe CAP. The current guidelines for manage-
ment of CAP do not recommend invasive studies when
clinical response is appropriate. Second, for our study
we enrolled patients after they had received antibiotic
treatment. We therefore did not have cytokine levels for
those patients prior to initiating their treatment. Third,
to improve the robustness of our results, we could ideally
have been controlled for patient age and pneumonia sever-
ity. However, our study draws upon a single-hospital co-
hort, and hence upon a limited number of patients. This,
and the aforementioned difficulties in collecting data from
NCAP patients, including the BAL procedure, prevented
our being able to conduct a multivariate analysis for this
study.Conclusions
Our study shows that after 72 hours of antibiotic ther-
apy, NCAP patients treated with macrolide containing
regimens have lower cytokine levels in both compart-
ments (systemic and pulmonary) than those treated with
non-macrolide regimens. This supports the immuno-
modulatory effect of macrolides on cytokine profiles
during the course of treatment. That effect seems to
contribute to faster resolution and earlier clinical stabil-
ity. Further randomized trials are needed to confirm the
benefit of macrolide therapy in NCAP patients.
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